Innovative and accredited continuing medical education
for today’s practicing clinicians.

CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.

  • Expert-led insights to improve patient outcomes

  • Multi-modal courses to suit all learning styles

  • Timely topics for relevant application to practice

  • Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials

  • A commitment to collective mindfulness 

Bipolar Disorder Education Collection by CME Institute

Recent courses

  • Self-study / Enduring
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
Drs Goldberg, Swartz, and DelBello discuss the spectrum of bipolar disorder, from major depressive disorder to bipolar I, and assessment strategies for establishing accurate diagnoses, including age, gender, signs and symptoms, and comorbidities to facilitate appropriate treatments and improve patient outcomes.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
Treating bipolar I and bipolar II depression is not one-size-fits-all. Learn from field experts about practice guidelines, novel agents, and approaches to developing personalized treatment plans for patients with bipolar depression type I and type II.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
Dr Goldberg describes the role of the clinician as that of a travel agent, asking the patient, “Where do you want to go; what do you want it to be like there; how do you want to get there;” etc, then providing the patient with the related evidence-supported information. Learn how to become your patients’ travel agent for their journey through optimizing treatment strategies for type I and type II bipolar disorder.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
Adopting consensus guidelines while applying new evidence on the latest treatment options can often be a matter of balancing risks, benefits, and tolerability when addressing acute episodes in bipolar I disorder. Sit in on the discussion between three experts as they discuss guideline-directed treatment strategies that address manic and mixed episodes in patients with bipolar I disorder, and listen to one patient’s journey to hope and recovery.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Depression
  • Bipolar Disorder
  • Bipolar Depression
Involving patients in designing their own treatment strategies according to their tolerability criteria can help combat the 90% nonadherence rate in patients being treated for bipolar disorder. Find out from experts about best practices in addressing patient concerns and balancing tolerability with efficacy and adherence in treating patients with bipolar disorder.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Patient/Physician Communication
  • Neurology
  • Neuroimaging
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Functional Impairment
  • Diagnostic Tools
  • Education
Drs Anderson and Malone discuss the burden of, signs and symptoms of, diagnostic tools and criteria for mild cognitive impairment (MCI) and mild/early dementia and the benefits of early diagnosis. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Participation
  • Self-study / Enduring
  • Muscular Dystrophy
  • Psychopharmacology
  • Patient/Physician Communication
  • Obsessive-Compulsive and Related Disorders
  • Violence/Aggression
  • Sleep
  • Side Effects
  • Delivery of Care
  • Cognition
  • Child and Adolescent Psychiatry
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Diagnostic Tools
  • Weight
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Psychotic Disorders
  • Substance Use Disorders
  • COVID-19
Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Self-study / Enduring
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation
  • Journal
  • Mood Disorders
  • Depression
  • Electroconvulsive Therapy
In this chart review, LGBTQ people with treatment-resistant mood disorders had clinical features linked to worse outcomes, but their improvement with ECT was similar to that seen in non-LGBTQ patients.
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Participation

Pages

My Courses

Please login or create an account to view your activities.

Transcript

Please login or create an account to view your activities.